title: Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mele
authors.forename: Angela
authors.initials: A
authors.lastname: Giannotta
authors.forename: Salvatore
authors.initials: S
authors.lastname: Pinna
authors.forename: Giacomo
authors.initials: G
authors.lastname: Loseto
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Coppi
authors.forename: Claudio Maurizio
authors.initials: CM
authors.lastname: Brocca
authors.forename: Angela
authors.initials: A
authors.lastname: Melpignano
authors.forename: Giovanni
authors.initials: G
authors.lastname: Quarta
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D016330:Frail Elderly; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D011719:Pyrazines / Q000008:administration & dosage; D016879:Salvage Therapy; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide